Effective prevention of sorafenib-induced hand&amp;ndash;foot syndrome by dried-bonito broth

Kamimura, Kenya; Shinagawa-Kobayashi, Yoko; Goto, Ryo; Ogawa, Kohei; Yokoo, Takeshi; Sakamaki, Akira; Abe, Satoshi; Kamimura, Hiroteru; Suda, Takafumi; Baba, Hiroshi; Tanaka, Takayuki; Nozawa, Yoshinori; Koyama, Naoto; Takamura, Masaaki; Kawai, Hirokazu; Yamagiwa, Satoshi; Aoyagi, Yoshinobu; Terai, Shuji

doi:10.2147/cmar.s159370

Cited by 6 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, successful management in the HIS group, which tended to comprise cases with poorer hepatic reserve function, indicates that the combination of HIS with SOR may effectively prevent and manage clinical symptoms from toxicities induced by SOR. Regarding the effect of DBB and HIS on the antitumor effect of SOR, we have shown that DBB is effective for maintaining peripheral blood flow and preventing HFS induced by SOR treatment; in addition, no differences in tumor response were observed between the DBB group and the control group 4. This result is consistent with the results obtained with DBB and HIS in this study (Table 1).…”

Section: Discussionsupporting

confidence: 90%

“…Bonito ( Katsuwonus pelamis ) is known as katsuo in Japan, where DBB is easy to obtain and is used to add flavor to food. In this study, the patients in the DBB group ingested 150 mL of commercially available, highly concentrated rich extract of DBB packs (Honzukuri Ichiban Dashi Kiwami Katsuo) orally, once a day every day, for the entire period of the study, in consistency with the previous study 4. The control group consumed normal food, which sometimes (one or two times a week) contained the extract; however, the concentration was approximately 10-fold lower than that in the pack.…”

Section: Methodsmentioning

confidence: 74%

“…Therefore, challenges and future directions of this study involve the assessment of the efficacy of DBB and HIS in larger groups in multiple centers and of the long-term administration of DBB and/or HIS. In addition, as shown in our previous study,4 blood flow in the vessels of the hand and foot can be examined by Doppler ultrasound, and the combination of CT and ultrasound may further contribute to the monitoring of adverse events and develop an effective prevention methodology using DBB and HIS.…”

Section: Discussionmentioning

confidence: 82%

“…However, to the best of our knowledge, effective methods to prevent the adverse effects have not been developed to date. We previously reported that reduction of peripheral blood flow is associated with hand–foot syndrome and that dried bonito broth (DBB) can prevent progression of hand–foot syndrome by causing vasodilatation 4. In addition, vascular damage to normal vessels by SOR has been confirmed in a medaka fish model.…”

Section: Introductionmentioning

confidence: 94%

See 3 more Smart Citations

<p>Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine</p>

Sakai

Kamimura

Shinagawa-Kobayashi

et al. 2019

CMAR

Self Cite

View full text Add to dashboard Cite

Background: Sorafenib (SOR) is an anti-angiogenic chemotherapeutic that prolongs the survival rates of patients with hepatocellular carcinoma. However, SOR also damages normal vasculature and causes associated adverse events, including hand–foot syndrome and hypertension (HT). We previously reported in an animal study that vascular damage resulted in the narrowing of the normal vascular dimension area in medaka fish ( Oryzias ), and histidine (HIS), a major amino acid contained in dried bonito broth (DBB), prevented these changes. Therefore, in the study, we analyzed the effects of DBB and HIS on SOR-related vascular damages and associated adverse events in patients. Materials and methods: Three-dimensional (3D) vascular images of abdominal regions reconstituted from computed tomography were assessed to compare vascular diameter prior to and following SOR administration in groups receiving SOR monotherapy, DBB+SOR, and HIS+SOR. The clinical courses of hand–foot syndrome and HT and the toxicities of SOR in biochemical assays were monitored and compared between the groups. Correlations between hepatic function and SOR-related changes in the portal venous area dimension were also assessed. Results: SOR-related vascular damage revealed narrowing of the normal abdominal vasculature in the human body, which was monitored using 3D images. The damage was ameliorated by DBB and HIS, however, HIS had a more marked effect, particularly on the renal arteries and portal vein (PV). Maintenance of blood flow contributed to the maintenance of total cholesterol, prothrombin time, albumin (ALB), and renal functions. Changes in the 3D vascular area dimension of the PV and level of serum ALB were significantly correlated. The occurrences of the clinical symptoms of hand–foot syndrome and HT were lower in the DBB- and HIS-treated groups. Conclusion: Our results clearly demonstrate that DBB and HIS prevented SOR-related abdominal vascular damage and effectively maintained hepatic function, and prevented clinical symptoms and toxicity. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000025937 and UMIN000026898).

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Methodsmentioning

confidence: 74%

Section: Discussionmentioning

confidence: 82%

Section: Introductionmentioning

confidence: 94%

See 2 more Smart Citations

<p>Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine</p>

Sakai

Kamimura

Shinagawa-Kobayashi

et al. 2019

CMAR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Inhibition of platelet-derived growth factor receptors (PDGFRs) and c-Kit in the eccrine glands of the dermis and epidermis of the palms and soles may contribute to HFSR [22,23]. A decrease in peripheral blood flow following sorafenib treatment has also been linked to the emergence of this AE [24]. Hypertension may result from TKI inhibition of vascular endothelial growth factor (VEGF)-mediated nitric oxide synthase upregulation, thereby inhibiting vasomotor function and promoting degeneration of small blood vessels [25].…”

Section: Association Of Tki Aes With Positive Treatment Outcomesmentioning

confidence: 99%

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma

Rimassa

Danesi

Pressiani

et al. 2019

Cancer Treatment Reviews

175

163

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase inhibitors (TKIs) that target, in part, vascular endothelial growth factor receptors, and are approved in various regions of the world for the treatment of advanced HCC. All these agents are associated with a range of adverse events (AEs) that can have a substantial impact on patients' healthrelated quality of life. Fatigue, diarrhoea, hand-foot skin reaction, nausea, vomiting, decreased appetite, hypertension and weight loss are among the most common AEs experienced with these four TKIs. In this review, we discuss strategies for the management of these AEs in patients with advanced HCC, with the aim of maximizing treatment benefits and minimizing the need for TKI treatment discontinuation. We also consider potential TKI-drug interactions and discuss the use of TKIs in patients with liver dysfunction or who have experienced tumour recurrence after liver transplantation. Use of appropriate AE management strategies and avoidance of contraindicated drugs should help patients with advanced HCC to achieve optimal outcomes with TKIs.

show abstract

A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma

Abuhelwa

Badaoui

Yuen

et al. 2022

Cancer Chemother Pharmacol

View full text Add to dashboard Cite

Purpose Sorafenib is an effective therapy for advanced hepatocellular carcinoma (HCC). Hand–foot syndrome (HFS) is a serious adverse effect associated with sorafenib therapy. This study aimed to develop an updated clinical prediction tool that allows personalized prediction of HFS following sorafenib initiation. Methods Individual participant data from Phase III clinical trial NCT00699374 were used in Cox proportional hazard analysis of the association between pre-treatment clinicopathological data and grade ≥ 3 HFS occurring within the first 365 days of sorafenib treatment for advanced HCC. Multivariable prediction models were developed using stepwise forward inclusion and backward deletion and internally validated using a random forest machine learning approach. Results Of 542 patients, 116 (21%) experienced grades ≥ 3 HFS. The prediction tool was optimally defined by sex (male vs female), haemoglobin (< 130 vs ≥ 130 g/L) and bilirubin (< 10 vs 10–20 vs ≥ 20 µmol/L). The prediction tool was able to discriminate subgroups with significantly different risks of grade ≥ 3 HFS (P ≤ 0.001). The high (score = 3 +)-, intermediate (score = 2)- and low (score = 0–1)-risk subgroups had 40%, 27% and 14% probability of developing grade ≥ 3 HFS within the first 365 days of sorafenib treatment, respectively. Conclusion A clinical prediction tool defined by female sex, high haemoglobin and low bilirubin had high discrimination for predicting HFS risk. The tool may enable improved evaluation of personalized risks of HFS for patients with advanced HCC initiating sorafenib.

show abstract

Effective prevention of sorafenib-induced hand–foot syndrome by dried-bonito broth

Cited by 6 publications

References 17 publications

<p>Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine</p>

<p>Effective prevention of sorafenib-related vascular damage induced adverse events and maintenance of hepatic function by dried bonito broth and histidine</p>

Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma

A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma

Contact Info

Product

Resources

About